Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I or II Clinical Trial Evaluating the Safety and Efficacy of NCR300 Injection in Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation

NCT06441084 is registered in ClinicalTrials.gov with Nuwacell Biotechnologies Co., Ltd. as lead sponsor.

NCT NCT06441084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06441084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I or II Clinical Trial Evaluating the Safety and Efficacy of NCR300 Injection in Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation
Lead sponsor
Nuwacell Biotechnologies Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 30, 2024
Completion date
December 31, 2031
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia